UB Paderborn / Katalog / Suche / in CDI

ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC

Annals of surgical oncology, 2022-03, Vol.29 (3), p.1645-1646

2022

Link zum Volltext

Verfügbarkeit prüfen

External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

Annals of surgical oncology, 2022-03, Vol.29 (3), p.1637-1644

2022

Link zum Volltext

Verfügbarkeit prüfen

ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

Annals of surgical oncology, 2022-03, Vol.29 (3), p.1647-1648

2022

Link zum Volltext

Verfügbarkeit prüfen

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model

Cancer Immunology, Immunotherapy, 2021-08, Vol.70 (8), p.2291-2300

2021

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration

Annals of surgical oncology, 2022-10, Vol.29 (11), p.7010-7017

2022

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

BMC cancer, 2022-08, Vol.22 (1), p.1-851, Article 851

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma

Melanoma research, 2024-02, Vol.34 (1), p.63

2024

Link zum Volltext

Verfügbarkeit prüfen

ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma—An International Multi-institutional Collaboration

Annals of surgical oncology, 2022-10, Vol.29 (11), p.7018-7018

2022

Link zum Volltext

Verfügbarkeit prüfen

Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis

Critical reviews in oncology/hematology, 2022-07, Vol.175, p.103705, Article 103705

2022

Link zum Volltext

Verfügbarkeit prüfen

The use of FDG‐PET/CT to detect early recurrence after resection of high‐risk stage III melanoma

Journal of surgical oncology, 2020-12, Vol.122 (7), p.1328-1336

2020

Link zum Volltext

Verfügbarkeit prüfen

Talimogene laherparepvec monotherapy for head and neck melanoma patients

Melanoma research, 2023-02, Vol.33 (1), p.66

2023

Link zum Volltext

Verfügbarkeit prüfen

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)

Journal of surgical oncology, 2021-12, Vol.124 (7), p.1161-1165

2021

Link zum Volltext

Verfügbarkeit prüfen

A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma

Journal of surgical oncology, 2019-11, Vol.120 (6), p.1056-1057

2019

Link zum Volltext

Verfügbarkeit prüfen

Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective

Journal of immunotherapy (1997), 2022-07, Vol.45 (6), p.263

2022

Link zum Volltext

Verfügbarkeit prüfen

External validation of a Dutch predictive nomogram for complete response to T-VEC in an independent American patient cohort

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9563-9563

2021

Link zum Volltext

Verfügbarkeit prüfen

Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9607-TPS9607

2022

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9546-9546

2023

Link zum Volltext

Verfügbarkeit prüfen

The use of PET/CT to detect early recurrence after resection of high-risk stage III melanoma, prior to the start of adjuvant therapy and during follow-up

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e22039-e22039

2020

Link zum Volltext

Verfügbarkeit prüfen

The value of lymph node ultrasound and whole body PET/CT in stage IIB/C patients prior to SLNB

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e22079-e22079

2020

Link zum Volltext

Verfügbarkeit prüfen

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

Cancer, 2021-07, Vol.127 (13), p.2251-2261

2021

Link zum Volltext

Verfügbarkeit prüfen

Rate of complete and durable responses of intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma and association with tumor load

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e22089-e22089

2020

Link zum Volltext

Verfügbarkeit prüfen

Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis

Journal of the American College of Surgeons, 2021-04, Vol.232 (4), p.424-431

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

Journal for immunotherapy of cancer, 2022-08, Vol.10 (8), p.e004417

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC

External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model

Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience

Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma

ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma—An International Multi-institutional Collaboration

Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis

The use of FDG‐PET/CT to detect early recurrence after resection of high‐risk stage III melanoma

Talimogene laherparepvec monotherapy for head and neck melanoma patients

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)

A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma

Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective

External validation of a Dutch predictive nomogram for complete response to T-VEC in an independent American patient cohort

Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial

Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial

The use of PET/CT to detect early recurrence after resection of high-risk stage III melanoma, prior to the start of adjuvant therapy and during follow-up

The value of lymph node ultrasound and whole body PET/CT in stage IIB/C patients prior to SLNB

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

Rate of complete and durable responses of intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma and association with tumor load

Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

Suchergebnisse filtern